Can bupropion (Wellbutrin) be prescribed concurrently with sofosbuvir‑velpatasvir?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Wellbutrin Be Prescribed with Sofosbuvir-Velpatasvir?

Yes, bupropion (Wellbutrin) can be safely prescribed concurrently with sofosbuvir-velpatasvir, as there is no clinically significant drug interaction between these medications.

Pharmacologic Rationale

Bupropion is primarily metabolized by CYP2B6 and is also a substrate and inhibitor of CYP2D6 1. Sofosbuvir-velpatasvir's interaction profile is well-defined: velpatasvir undergoes slow metabolic turnover by CYP2B6, CYP2C8, and CYP3A4, while both sofosbuvir and velpatasvir are substrates of P-gp and BCRP transporters 2.

The critical distinction here is that bupropion is neither a potent P-gp inducer nor a potent CYP inducer—the two mechanisms that would contraindicate use with sofosbuvir-velpatasvir 3. The EASL guidelines specifically list contraindicated drugs as potent P-gp or CYP inducers such as rifampicin, carbamazepine, phenobarbital, phenytoin, and St. John's wort 3. Bupropion does not appear on this list.

Key Interaction Considerations

What Sofosbuvir-Velpatasvir Actually Affects:

  • Velpatasvir inhibits P-gp, BCRP, OATP1B1, OATP1B3, and OATP2B1 transporters 2
  • This means sofosbuvir-velpatasvir can increase exposure of drugs that are substrates of these transporters
  • Bupropion is not a substrate of these transporters in a clinically meaningful way

What Could Theoretically Happen:

Since velpatasvir has slow metabolic turnover by CYP2B6 and bupropion is metabolized by CYP2B6, there could theoretically be minor competitive metabolism. However, the FDA label for sofosbuvir-velpatasvir explicitly states that it "may be coadministered with P-gp, BCRP, and CYP inhibitors" 2, and bupropion acts primarily as a CYP2D6 inhibitor, not a CYP2B6 inhibitor.

Clinical Bottom Line

No dose adjustment is needed for either medication when prescribed together. The absence of bupropion from both the EASL contraindicated/cautionary drug lists 3 and the FDA drug interaction tables 2 indicates no clinically significant interaction exists.

Important Caveats:

  • Monitor for standard bupropion side effects (seizure risk, neuropsychiatric effects) as you would in any patient 1
  • Ensure the patient is not on other medications that lower seizure threshold when adding bupropion 1
  • The hepatitis C treatment itself may alter hepatic function, which could theoretically affect drug metabolism, but this is not specific to bupropion and applies to all concomitant medications 2

This combination is safe to prescribe without special monitoring beyond standard clinical care for each medication individually.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.